Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model

Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma

(2016) Curtis A. Clark et al.   CANCER RESEARCH

Immune checkpoint inhibition in ovarian cancer

(2016) Junzo Hamanishi et al.   INTERNATIONAL IMMUNOLOGY

Multiple Differential Networks Strategy Reveals Carboplatin and Melphalan-Induced Dynamic Module Changes in Retinoblastoma

(2016) Cui Chen et al.   MEDICAL SCIENCE MONITOR

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer

(2015) Z Zhang et al.   CANCER GENE THERAPY

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

(2015) J. Peng et al.   CANCER RESEARCH

Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer

(2015) Zhiqiang Guo et al.   Journal of Translational Medicine

Immune checkpoint modulation: Rational design of combination strategies

(2015) Dmitriy Zamarin et al.   PHARMACOLOGY & THERAPEUTICS

PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer

(2014) Zhiqiang Guo et al.   PLoS One

Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer

(2014) Charlotte S Marcus et al.   Journal of Cancer

Antibody-based immunotherapy for ovarian cancer: where are we at?

(2013) B. W. C. Tse et al.   ANNALS OF ONCOLOGY

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Counteracting immunosuppressive cofactor B7-H1 may enhance the effects of chemotherapy in cancer patients

(2013) Qiong Liu et al.   Immunotherapy

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer

(2013) Zhiqiang Guo et al.   Journal of Translational Medicine

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immunotherapy earns its spot in the ranks of cancer therapy

(2012) Drew Pardoll et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Doublet Chemotherapy in the Elderly Patient With Ovarian Cancer

(2012) Min Y. Teo et al.   ONCOLOGIST

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Immunotherapy in ovarian cancer

(2012) Gina M. Mantia-Smaldone et al.   Human Vaccines & Immunotherapeutics

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

(2007) Ping Zhang et al.   MOLECULAR IMMUNOLOGY